Effect of Drug Clinical Trial
— OAIEOfficial title:
Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Two-arm, Phase 2 Trial
Verified date | May 2024 |
Source | Peking University People's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Apatinib has led to positive responses in the treatment of osteosarcoma refractory to first-line chemotherapy. However, apatinib demonstrates only short-lived activity, and the disease control of musculoskeletal lesions is worse than that of pulmonary lesions. This treatment failure has been partly overcome by the addition of ifosfamide and etoposide (IE). We have ever retrospectively compared the activity of apatinib + IE in relapsed or refractory osteosarcoma in two sarcoma centers in China and concluded that for osteosarcoma with multiple sites of metastasis, apatinib + IE demonstrated clinically meaningful antitumor activity and delayed disease progression in patients with recurrent or refractory osteosarcoma after failure of chemotherapy. However to overcome the influence of other interventions on the outcome, we are currently performing a prospective trial to investigate this combination, from which more accurate data on this treatment strategy are expected.
Status | Completed |
Enrollment | 81 |
Est. completion date | November 26, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. advanced recurrent and refractory osteosarcoma confirmed by histopathology; 2. initial treatment in the Orthopedic/Oncology Departments of Peking University People's Hospital or Peking University Shougang Hospital; 3. progression less than 6 months after first-line chemotherapy with a combination of high-dose methotrexate, doxorubicin, cisplatin and ifosfamide (first-line chemotherapy); 4. measurable lesions according to the Response Evaluation Criteria for Solid Tumors (RECIST 1.1) ; 5. Eastern Cooperative Oncology Group performance status = 1 ; 6. acceptable haematologic, hepatic, and renal function. Exclusion Criteria: 1. those who had been previously treated with antiangiogenic TKIs and single IE chemotherapy; 2. those who had severe or uncontrolled medical disorders that could jeopardize the outcomes of the study. These confounding conditions included, cardiac clinical symptoms or disease with left ventricular ejection fraction<50%, and hypertension that could not be well controlled with antihypertensive drugs.; 3. all patients were assessed by the sarcoma board including a thoracic surgeon with at least 10 years surgical experience. Patients with lung metastases only were carefully assessed for eligibility for metastasectomy, of whom those who were suitable for surgery were excluded from this study; 4. weight loss of 20% or more before illness; 5. brain or leptomeningeal metastasis; 6. surgical procedure or radiotherapy within 4 weeks of enrollment; 7. activegastroduodenal ulcer, previous condition associated with risk of bleeding or requiring anticoagulation; 8. proteinuria or hematuria, denutrition with albuminemia <25 g/L; 9. women who were pregnant or breast feeding, other malignancy; 10. positive HBV/HCV/HIV serology, and known allergy to the experimental agents. |
Country | Name | City | State |
---|---|---|---|
China | Peking University People's Hospital | Beijing | Beijing |
China | Peking University People's Hospital | Beijing | Beijing |
China | Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University | Nanjing | Jiangsu |
China | Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine | Shanghai | Shanghai |
China | Shanghai Jiao Tong University Affiliated Sixth People's Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Peking University People's Hospital | Jiangsu HengRui Medicine Co., Ltd. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression free survival | from the start of target treatment until disease progression or death, whichever came first. | 2 years | |
Secondary | Overall survival | from the date of treatment initiation to death from any cause. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04549012 -
Determination of Blood Loss After CS
|
Early Phase 1 | |
Active, not recruiting |
NCT06114758 -
Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
|
||
Completed |
NCT05076253 -
Efficacy of Ivermectin in COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
Not yet recruiting |
NCT04562493 -
Comparative Effect of Transforaminal Injection of Magnesium Sulphate Versus Ozone Therapy on Oxidative Stress Biomarkers in Lumbar Disc Related Radicular Pain
|
N/A | |
Completed |
NCT04762147 -
Comparison of Perioperative Analgesia Between Intravenous Paracetamol and Fentanyl for Rigid Hysteroscopy
|
Phase 3 | |
Not yet recruiting |
NCT05510986 -
The Effect of Oxycodone Hydrochloride on CRBD After TURBT Under General Anesthesia
|
N/A | |
Completed |
NCT06432309 -
Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease
|
N/A | |
Recruiting |
NCT05092074 -
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
|
||
Recruiting |
NCT05968885 -
Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity
|
Phase 4 | |
Recruiting |
NCT05595044 -
Effect of Vitamin D Therapy in Autism Spectrum Disorder
|
Phase 1 | |
Not yet recruiting |
NCT06100510 -
PFA 100 Evaluation and Reference Interval HOACNY
|
Phase 4 | |
Completed |
NCT05060913 -
Emla Cream Versus Benzocaine on Analgesia
|
Early Phase 1 | |
Not yet recruiting |
NCT05293119 -
Role of Tofacitinib in Vitiligo Patients
|
Early Phase 1 | |
Not yet recruiting |
NCT06414018 -
Effect of Equivalent Dose Sufentanil and Afentanil in Bronchoscopic Treatment
|
N/A | |
Recruiting |
NCT05786859 -
The Efficacy and Safety of Rifaximin Treatment
|
Early Phase 1 | |
Not yet recruiting |
NCT06290219 -
The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction
|
Phase 3 | |
Recruiting |
NCT05482451 -
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
|
Early Phase 1 | |
Not yet recruiting |
NCT04892212 -
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05918146 -
Dextrose Therapy on Physical Therapy in Subdeltoid Bursitis
|
Phase 4 |